Need for circular use of materials in construction Construction and demolition waste are being recycled on a large scale to use as a foundation for e.g. roads, but recycled building materials are hardly ever used in the construction of buildings.
Tool for risk assessment of nanomaterials in cosmetics Both regulators and manufacturers need to evaluate and manage consumer health risks that may be posed by the use of nanomaterials in cosmetics.
Nanotechnology increasingly used in medical devices The application of nanotechnology to design and produce medical devices is increasing. RIVM provides an overview of nanotechnology enabled medical devices.
Eating less salt can prevent tens of thousands of heart attacks and strokes Lowering the amount of salt in processed foods or choosing low-salt alternatives can lead to substantial health benefits when it comes to cardiovascular disease.
Large differences in childhood obesity in Europe The percentage of overweight (including obesity) among 6-9-year-old children differs between European countries, ranging from 18 to 57%. Percentages are highest in southern European countries.
Cost-effective risk assessment of nanomaterials may be feasible Companies, authorities and scientists can save time, money and test animals in the risk assessment of nanomaterials by using available data.
New Lyme disease study in the Netherlands At the start of the “Tick Awareness Week”, the Dutch National Institute for Public Health and the Environment (RIVM) and Wageningen UR are commencing a large-scale study on the long-term effects of
Innovation required in risk assessment of nanoparticles The currently existing models and techniques provide insufficient certainties in the assessment of the harmfulness of nanoparticles and nanomaterials to people and the environment.
RIVM film about nanomaterials RIVM contributes to the safe use of nanomaterials through research, alerts and policy consultations, and this work is demonstrated in a short informative film.
RIVM to research safe design for new nanoparticles RIVM will be working alongside a consortium of 23 international partners on a safe design for ‘new’ nanoparticles.